#Endocrine | #GrowthHormone | #Metabolic

Tesamorelin — GHRH Analog Research Peptide (RUO)

Tesamorelin is a synthetic 44-amino-acid polypeptide analog of Growth Hormone-Releasing Hormone (GHRH). Featuring an N-terminal trans-3-hexanoic acid modification, Tesamorelin exhibits enhanced stability relative to native GHRH and is widely used as a reference standard for investigating hypothalamic–pituitary signaling and pulsatile growth hormone secretion dynamics in experimental models.

Peptide Name:

Tesamorelin

Peptide Class:

GHRH Analog (Synthetic)

Sequence Length:

44 Amino Acids

Structural Modification:

N-terminal trans-3-hexanoic acid

Primary Research Focus:

GHRH receptor signaling, GH pulsatility, visceral adipose tissue models

CAS Number:

218949-48-5

Chemical Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight

~5,136 g/mol

Store lyophilized peptide at −20 °C. Protect from light and moisture.

Sterile bacteriostatic water. Preparation should be performed under aseptic conditions. Reconstituted material is not intended for long-term storage.

GHRH Receptor Signaling & Pituitary Axis

Tesamorelin functions as a potent agonist at the Growth Hormone-Releasing Hormone (GHRH) receptor located on somatotroph cells of the anterior pituitary gland.

Receptor Binding: Studies assess binding affinity and specificity to pituitary GHRH-R compared with native GHRH (1-44).
cAMP Activation: G-protein–coupled receptor signaling is evaluated through intracellular cAMP production leading to growth hormone release.

Growth Hormone Pulsatility & Endocrine Feedback

Unlike non-pulsatile growth hormone secretagogues, Tesamorelin is used to preserve physiological circadian pulsatility of GH secretion.

Feedback Loops: Interaction with somatostatin-mediated negative feedback mechanisms is examined in vivo.
IGF-1 Induction: Downstream hepatic synthesis of insulin-like growth factor-1 (IGF-1) following receptor activation is quantified.

Adipose Tissue & Lipid Metabolism Research

Tesamorelin is commonly employed as a reference compound in models investigating visceral adipose tissue dynamics.

Lipolysis: Measurement of triglyceride breakdown rates in visceral adipocytes versus subcutaneous fat depots.
Fat Distribution: Evaluation of selective reductions in ectopic visceral adipose tissue without proportional loss of subcutaneous fat.

Hepatic Lipid & Ectopic Fat Signaling

Research explores Tesamorelin’s role in hepatic lipid handling within metabolic dysfunction models.

De Novo Lipogenesis: Downregulation of enzymes involved in hepatic lipid synthesis.
Liver Health Markers: Monitoring changes in ALT and AST levels following GHRH analog exposure in animal studies.

Muscle Composition & Anabolic Signaling Models

Growth hormone and IGF-1–mediated anabolic signaling pathways are examined using Tesamorelin in experimental settings.

Myocyte Hypertrophy: In-vitro analysis of muscle fiber size and protein synthesis rates.
Body Composition: Assessment of lean mass retention relative to fat mass reduction in animal models.

Neurological & Cognitive Research Context

Early-stage research investigates potential extra-pituitary roles of GHRH signaling.

Cognitive Function: Exploratory studies on executive function and memory in aging models.
Neurotransmitter Modulation: Evaluation of GHRH receptor expression in extra-pituitary brain regions.

Peripheral Nerve & Regenerative Signaling Models

Initial investigations assess the regenerative capacity of the GHRH axis.

Nerve Regeneration: Measurement of axonal regrowth and functional recovery in rodent nerve-injury models.

Research Limitations

Species Specificity: GHRH signaling is conserved, but receptor density and feedback sensitivity differ between rodents and humans.
Glucose Metabolism: Activation of the GH axis may induce insulin resistance; separating this effect from lipolytic benefits requires careful model selection.
Short Functional Half-Life: Despite stabilization, specific dosing protocols are required to replicate physiological pulsatility in vivo.

References

Spooner, L. M., & Olin, J. L. (2012).
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
Annals of Pharmacotherapy.
Zhou, Y., et al. (2020).
Clinical potential of GHRH analogs in aging and neurodegenerative diseases.
Frontiers in Aging Neuroscience.
Stanley, T. L., et al. (2011).
Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
Journal of Clinical Endocrinology & Metabolism.
Falutz, J., et al. (2010).
Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation.
AIDS.
Friedman, G. S., et al. (2013).
Effects of GHRH analog tesamorelin on liver enzymes and hepatic steatosis.
Hepatology Research.

The compound listed below is referenced in research contexts related to the mechanisms discussed in this article.

Tesamorelin is a chemical reference standard intended strictly for in-vitro and laboratory research applications (e.g., receptor binding assays, metabolic modeling, cell culture studies). It is not a drug, dietary supplement, vaccine adjuvant, or therapeutic product. It is not intended for human consumption, injection, or clinical use. All handling must be performed by qualified professionals in a laboratory setting.

Tesamorelin — GHRH Analog Research Peptide (RUO)

Peptide Name:

Peptide Class:

Sequence Length:

Structural Modification:

Primary Research Focus:

CAS Number:

Chemical Formula

Molecular Weight

Age Verification Required

GLP2-T

Thymosin Alpha-1 (TA1)

Tesamorelin

TB-500

SS-31

Semax

Selank

GLP3-R

PT-141